INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
Institut Curie, PSL Research University, CNRS UMR3348, INSERM U1278, Orsay, France; Université Paris Sud, Université Paris-Saclay, CNRS UMR3348, INSERM U1278, Orsay, France; Equipe Labellisée Ligue Nationale Contre le Cancer, Orsay, France.
Cell. 2020 Nov 12;183(4):860-874. doi: 10.1016/j.cell.2020.10.027.
Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug treatment and constitute a major cause of treatment failure. These cells are characterized by their slow proliferation, highly flexible energy consumption, adaptation to their microenvironment, and phenotypic plasticity. Mechanisms that underlie their persistence offer highly coveted and sought-after therapeutic targets, and include diverse epigenetic, transcriptional, and translational regulatory processes, as well as complex cell-cell interactions. Although the successful clinical targeting of persistent cancer cells remains to be realized, immense progress has been made in understanding their persistence, yielding promising preclinical results.
持续性癌细胞是指在癌症药物治疗后存活下来的离散且通常无法检测到的细胞，是导致治疗失败的主要原因。这些细胞的特征是增殖缓慢、能量消耗高度灵活、能适应其微环境以及表现出表型可塑性。它们之所以能够持续存在，是因为存在多种备受追捧的治疗靶点，包括各种表观遗传、转录和翻译调控过程以及复杂的细胞间相互作用。尽管成功地针对持续性癌细胞进行临床治疗的目标尚未实现，但在理解它们的持续性方面已经取得了巨大的进展，为临床前研究带来了有希望的结果。
